IMMC-OTCBB
Tuesday Feb. 2, 1999- Wall Street Journal Reports that Pharmaceutical companies continue to be undervalued in today's market. The Report further explains that many Venture Capital Firms have and will continue to invest further in small cap Pharmaceutical
companies. The article foretold that many of these investment groups make positions in the public traded small drug companies because the risk factors are smaller then most investments in private CO's.
Those of you(LIKE ME) who have a position in IMMC should continue to feel confident that many investment circles see small cap Drug companies as a REAL BUY !
REMEMBER: IMMUNIS Corp. (IMMC-OTCBB) has a 25% interest in the profit of all sales outside of China. IMMC derives its revenue from BiOTECH LIMITED, the developer of DIAB-II, which in turn sell/market this drug to their customers (http://www.biotechltd.com). IMMC has NO DEBT, 600,000 shares PUBLIC FLOAT, Nominal Overhead, No capital expenditures, & Averages a 60% margin. BiOTECH's strong world wide medical supporters and on-going Distribution/Marketing agreements
throughout Latin America enables IMMC to earn substantial returns with LITTLE risk and with GREAT returns on capital. Additionally, The December 21 issue of Fortune Magazine said: "Pharmaceutical companies are almost unique in their ability to generate strong earnings growth in any economic climate". The same article reported that many
Wall Street Analysts, wallstreetresearch.net, are excited
about any type of new drug with empirical evidence. IMMC has many investors, analysts, pharmacists, and doctors excited about this company! IMMC-OTCBB! |
